Koyfin Home > Directory > Health Care > Adamas Pharma > Long-Term Debt

Adamas Pharma Long-Term Debt Chart (ADMS)

Adamas Pharma annual/quarterly Long-Term Debt from 2017 to 2020.
  • Adamas Pharma Long-Term Debt for the quarter ending June 06, 2020 was $126m a 1.76% increase of 2m year over year
  • Adamas Pharma Long-Term Debt for the last 12 months ending June 06, 2020 was $126m a 1.76% increase of 2m year over year
  • Adamas Pharma Annual Long-Term Debt for 2019 was $126m a 6.54% increase of 8m from 2018
  • Adamas Pharma Annual Long-Term Debt for 2018 was $117m a 12.61% increase of 15m from 2017
  • Adamas Pharma Annual Long-Term Debt for 2017 was $103m
Other Cash Flow Metrics:
  • Adamas Pharma Cash Flow from Operations for the quarter ending December 12, 2018 was $-24m a -5.06% increase of 1m year over year
  • Adamas Pharma Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-33m a 50.48% decrease of -17m year over year
  • Adamas Pharma Total Revenue for the quarter ending September 09, 2018 was $11m a 94.65% increase of 10m year over year
View Chart On Koyfin

Quarterly ADMS Long-Term Debt Data

06/2020$126m
03/2020$126m
12/2019$126m
09/2019$124m
06/2019$122m
03/2019$120m
12/2018$117m
09/2018$115m
06/2018$111m
03/2018$107m

Annual ADMS Long-Term Debt Data

2019$126m
2018$117m
2017$103m